Advertisement

The Impact of Medication Adherence on Coronary Artery Disease Costs and Outcomes: A Systematic Review

      Abstract

      Background

      Given the huge burden of coronary artery disease and the effectiveness of medication therapy, understanding and quantifying known impacts of poor medication adherence for primary and secondary prevention is crucial. We sought to systematically review the literature on this topic area with a focus on quantified cost and clinical outcomes related to adherence.

      Methods

      We conducted a systematic review of the literature between 1966 and November 2011 using a fixed search strategy, multiple reviewers, and a quality rating scale. We found 2636 articles using this strategy, eventually weaning them down to 25 studies that met our inclusion criteria. Three reviewers independently reviewed the studies and scored them for quality using the Newcastle Ottawa Scoring Scale.

      Results

      We found 5 studies (4 of which focused on statins) that measured the impact of medication adherence on primary prevention of coronary artery disease and 20 articles that focused on the relationship between medication adherence to costs and outcomes related to secondary prevention of coronary artery disease. Most of these latter studies focused on antihypertensive medications and aspirin. All controlled for confounding comorbidities and sociodemographic characteristics, but few controlled for likelihood of adherent patients to have healthier behaviors (“healthy adherer effect”). Three studies found that high adherence significantly improves health outcomes and reduces annual costs for secondary prevention of coronary artery disease (between $294 and $868 per patient, equating to 10.1%-17.8% cost reductions between high- and low-adherence groups). The studies were all of generally of high quality on the Newcastle Ottawa Scale (median score 8 of 9).

      Conclusions

      Increased medication adherence is associated with improved outcomes and reduced costs, but most studies do not control for a “healthy adherer” effect.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heidenreich P.A.
        • Trogdon J.G.
        • Khavjou O.A.
        • et al.
        Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
        Circulation. 2011; 123: 933-944
        • DiMatteo M.R.
        • Giordani P.J.
        • Lepper H.S.
        • Croghan T.W.
        Patient adherence and medical treatment outcomes: a meta-analysis.
        Med Care. 2002; 40: 794-811
        • Salas M.
        • Hughes D.
        • Zuluaga A.
        • et al.
        Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.
        Value Health. 2009; 12: 915-922
        • Roebuck M.C.
        • Liberman J.N.
        • Gemmill-Toyama M.
        • Brennan T.A.
        Medication adherence leads to lower health care use and costs despite increased drug spending.
        Health Aff (Millwood). 2011; 30: 91-99
        • Bechtel C.
        • Ness D.L.
        If you build it, will they come?.
        Health Aff (Millwood). 2010; 29: 914-920
        • Bouchard M.H.
        • Dragomir A.
        • Blais L.
        • et al.
        Impact of adherence to statins on coronary artery disease in primary prevention.
        Br J Clin Pharmacol. 2007; 63: 698-708
        • Breekveldt-Postma N.S.
        • Penning-van Beest F.J.
        • Siiskonen S.J.
        • et al.
        The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke.
        Curr Med Res Opin. 2008; 24: 121-127
        • Corrao G.
        • Conti V.
        • Merlino L.
        • et al.
        Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
        Clin Ther. 2010; 32: 300-310
        • Pittman D.G.
        • Chen W.
        • Bowlin S.J.
        • Foody J.M.
        Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations.
        Am J Cardiol. 2011; 107: 1662-1666
        • Perreault S.
        • Dragomir A.
        • Blais L.
        • et al.
        Impact of better adherence to statin agents in the primary prevention of coronary artery disease.
        Eur J Clin Pharmacol. 2009; 65: 1013-1024
        • Amin A.P.
        • Mukhopadhyay E.
        • Nathan S.
        • et al.
        Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population.
        Transl Res. 2009; 154: 78-89
        • Aubert R.E.
        • Yao J.
        • Xia F.
        • Garavaglia S.B.
        Is there a relationship between early statin compliance and a reduction in healthcare utilization?.
        Am J Manag Care. 2010; 16: 459-466
        • Chapman R.H.
        • Yeaw J.
        • Roberts C.S.
        Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
        BMC Cardiovasc Disord. 2010; 10: 29
        • Choudhry N.K.
        • Avorn J.
        • Glynn R.J.
        • et al.
        Full coverage for preventive medications after myocardial infarction.
        N Engl J Med. 2011; 365: 2088-2097
        • Corrao G.
        • Parodi A.
        • Nicotra F.
        • et al.
        Better compliance to antihypertensive medications reduces cardiovascular risk.
        J Hypertens. 2011; 29: 610-618
        • Gallagher E.J.
        • Viscoli C.M.
        • Horwitz R.I.
        The relationship of treatment adherence to the risk of death after myocardial infarction in women.
        JAMA. 1993; 270: 742-744
        • Gehi A.K.
        • Ali S.
        • Na B.
        • Whooley M.A.
        Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study.
        Arch Intern Med. 2007; 167: 1798-1803
        • Ho P.M.
        • Spertus J.A.
        • Masoudi F.A.
        • et al.
        Impact of medication therapy discontinuation on mortality after myocardial infarction.
        Arch Intern Med. 2006; 166: 1842-1847
        • Ho P.M.
        • Magid D.J.
        • Shetterly S.M.
        • et al.
        Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease.
        Arch Intern Med. 2008; 168: 271-276
        • Ho P.M.
        • Magid D.J.
        • Shetterly S.M.
        • et al.
        Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.
        Am Heart J. 2008; 155: 772-779
        • Irvine J.
        • Baker B.
        • Smith J.
        • et al.
        Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study.
        Psychosom Med. 1999; 61: 566-575
        • Kleiner S.A.
        • Vogt W.B.
        • Gladowski P.
        • et al.
        Beta-blocker compliance, mortality, and reinfarction: validation of clinical trial association using insurer claims data.
        Am J Med Qual. 2009; 24: 512-519
        • Newby L.K.
        • LaPointe N.M.
        • Chen A.Y.
        • et al.
        Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
        Circulation. 2006; 113: 203-212
        • Pittman D.G.
        • Tao Z.
        • Chen W.
        • Stettin G.D.
        Antihypertensive medication adherence and subsequent healthcare utilization and costs.
        Am J Manag Care. 2010; 16: 568-576
        • Rasmussen J.N.
        • Chong A.
        • Alter D.A.
        Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.
        JAMA. 2007; 297: 177-186
        • Shalev V.
        • Chodick G.
        • Silber H.
        • et al.
        Continuation of statin treatment and all-cause mortality: a population-based cohort study.
        Arch Intern Med. 2009; 169: 260-268
        • Spertus J.A.
        • Kettelkamp R.
        • Vance C.
        • et al.
        Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
        Circulation. 2006; 113: 2803-2809
        • Sun S.X.
        • Ye X.
        • Lee K.Y.
        • et al.
        Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
        Clin Ther. 2008; 30: 2217-2227
        • Wei L.
        • Wang J.
        • Thompson P.
        • et al.
        Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study.
        Heart. 2002; 88: 229-233
        • Dragomir A.
        • Cote R.
        • White M.
        • et al.
        Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting.
        Value Health. 2010; 13: 87-94
        • Dormuth C.R.
        • Patrick A.R.
        • Shrank W.H.
        • et al.
        Statin adherence and risk of accidents: a cautionary tale.
        Circulation. 2009; 119: 2051-2057
        • Piccini J.P.
        • Berger J.S.
        • O'Connor C.M.
        Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.
        Eur Heart J. 2009; 30: 1245-1253
        • Goldman L.
        • Epstein A.M.
        Improving adherence–money isn't the only thing.
        N Engl J Med. 2011; 365: 2131-2133